Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,682 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06230198Recruiting
Effect of a blood-saving technique on transfusions after heart surgery
This trial tests whether a technique called retrograde autologous priming (using the patient's own blood to prepare the heart-lung machine) can reduce the need for blood transfusions during heart surgery. It is looking at hospitals and surgical teams, not individual patients, so it's not a typical trial you can join directly.
Winnipeg, ManitobaAges 10–110 - NCT07047183RecruitingPhase 2
A study of venetoclax and azacitidine before stem cell transplant for MDS
This trial tests a combination of two drugs (venetoclax and azacitidine) given before a stem cell transplant to see if it improves outcomes for people with a certain type of myelodysplastic syndromes (MDS) that is higher risk. If you have higher-risk MDS and are planning a stem cell transplant, this may be an option.
Changchun, JilinAges 18 years+ - NCT07058519RecruitingPhase 2
Personalized osimertinib treatment guided by blood test for EGFR lung cancer
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06321198Recruiting
Modified stem cells for severe graft-versus-host disease
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
Hefei, AnhuiAges 4–70 - NCT05703971RecruitingPhase 1/Phase 2
Maintenance treatment with a gene therapy plus atezolizumab
This Phase 1/2 trial tests whether a gene therapy called Reqorsa given with atezolizumab can help people with extensive-stage small cell lung cancer (ES-SCLC) stay controlled after their first chemo. It may help by boosting the immune system to keep the cancer from growing again.
Lone Tree, ColoradoAges 18 years+ - NCT07169708Recruiting
Study of nivolumab and chemo before surgery for lung cancer
This trial looks at real-world outcomes in Taiwan for people with resectable non-small cell lung cancer (NSCLC) who get nivolumab combined with chemotherapy before surgery. It aims to understand how well this treatment works and how safe it is.
Kaohsiung CityAges 18 years+ - NCT07308106RecruitingPhase 2
Testing SKB571 for MET-mutated advanced lung cancer
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
ShanghaiAges 18–75 - NCT06853678Recruiting
Immunotherapy after first treatment for extensive stage small cell lung cancer
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07488546Enrolling by invitationPhase 1/Phase 2
HCL001 cell therapy for advanced liver cirrhosis
This trial tests a new cell injection called HCL001 for people with decompensated cirrhosis (advanced liver scarring causing complications). The goal is to see if it's safe and helps improve liver function. It may be an option if you've tried standard treatments and meet specific health criteria.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05931263RecruitingPhase 3
Tested Chi-BEAM vs BEAM before stem cell transplant for lymphoma
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
Nanjing, JiangsuAges 18–65 - NCT05150145Recruiting
Radiation versus observation for liver spread of small cell lung cancer
This trial compares giving liver-directed radiation to watching closely without radiation. It is for people with small cell lung cancer that has spread to the liver, to see whether radiation helps control the disease.
Guiyang, GuizhouAges 18–70 - NCT06692556RecruitingPhase 3
Radiation vs monitoring for high-risk skin cancer
This trial compares two strategies after surgery for a type of skin cancer (cutaneous squamous cell carcinoma) that has a high chance of coming back. One strategy gives radiation therapy to the area, while the other just watches and checks for any signs of recurrence. The goal is to see if radiation can prevent the cancer from returning.
Le Puy-en-Velay, Auvergne-Rhône-AlpesAges 18 years+ - NCT06083129RecruitingPhase 3
Preventing GVHD after stem cell transplant in older adults
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
AmiensAges 50–70 - NCT06678282Recruiting
Testing an investigational cell therapy for B-cell lymphoma or leukemia
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
Zhenzhou, HenanAges 18–75 - NCT07217301RecruitingPhase 3
Comparing TAK-928 to docetaxel for advanced lung cancer
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Jonesboro, ArkansasAges 18 years+ - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT07168317RecruitingPhase 2
Study of tislelizumab plus other drugs for new AITL lymphoma
This trial tests a combination of five drugs for people newly diagnosed with a rare type of lymphoma called angioimmunoblastic T-cell lymphoma (AITL). The goal is to see if this treatment helps control the cancer.
Xuzhou, JiangsuAges 18 years+ - NCT06671275Enrolling by invitationPhase 1
Testing CUD005 Injection for Advanced Liver Cirrhosis
This study tests an injection called CUD005 for people with advanced liver cirrhosis that is causing complications. The goal is to see if it is safe and can help improve liver function.
Hefei, AnhuiAges 18–75 - NCT07101588RecruitingPhase 4
Ruxolitinib and decitabine before stem cell transplant for AML
This trial tests whether adding two drugs (ruxolitinib and decitabine) to the standard chemotherapy before a stem cell transplant can help prevent leukemia from coming back. It is for people with acute myeloid leukemia who have a suitable donor and are otherwise healthy enough for transplant.
Beijing, Beijing MunicipalityAges 14–75 - NCT07085182RecruitingPhase 2
Tislelizumab plus radiation for advanced lung cancer
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Zibo, ShandongAges 18–75 - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+ - NCT06743477Recruiting
Super transplant for severe thalassemia in children
This trial tests a new type of transplant (called 'super transplantation') for children with severe thalassemia. It aims to help those who cannot get a fully matched donor or have chosen not to have standard treatments.
Kunming, YunnanAges 7–12 - NCT07538635RecruitingPhase 2
CAR-T cells plus stem cell transplant for aggressive lymphoma
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hangzhou, ZhengjiangAges 18 years+ - NCT06075563Recruiting
Total Lymphoid Irradiation for Children's Stem Cell Transplant
This trial tests a special type of radiation (total lymphoid irradiation) as part of the preparation for a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for children who need a transplant but don't have a fully matched sibling donor.
Hong KongAges Up to 18 years
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,682 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.